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Non-alcoholic steatohepatitis (NASH) is characterized by liver steatosis and lobular inflammation. It is unclear 
how the development of liver steatosis and the formation of inflammatory cell aggregates are related to each 
other. The present study investigated the longitudinal development of two forms of steatosis, micro- and 
macrovesicular steatosis, as well as lobular inflammation. ApoE*3Leiden.CETP (E3L.CETP) transgenic mice 
were fed a high-fat diet containing 1% w/w cholesterol (HFC) for 12 weeks to induce NASH. Livers were 
harvested in intervals of 4 weeks and analyzed by histological and biochemical techniques, as well as 
transcriptome and subsequent pathway analysis. Major findings were validated in independent NASH studies 
using other rodent models, i.e. HFD-treated C57BL/6J and LDLr-/-.Leiden mice. In E3L.CETP mice, 
microvesicular steatosis was rapidly induced and reached plateau levels after already 4 weeks of HFC treatment, 
while macrovesicular steatosis developed more gradually and progressed over time. Lobular inflammation 
increased after 4 weeks with a significant further progression towards the end of the study (12 weeks). 
Macrovesicular, but not microvesicular, steatosis was positively correlated with the number of inflammatory 
aggregates. This correlation was confirmed in a milder (C57BL/6J) and a more severe (LDLr-/-.Leiden) NASH 
model. Furthermore, collagen staining showed onset of perihepatocellular fibrosis in E3L.CETP mice after 12 
weeks of HFC treatment and transcriptome analysis substantiated the activation of pro-fibrotic pathways and 
genes. Notably, macrovesicular steatosis correlated positively with liver fibrosis in LDLr-/-.Leiden mice with 
pronounced fibrosis. In conclusion, this study shows that macrovesicular steatosis is associated with lobular 
inflammation and liver fibrosis in rodent models and highlights the importance of this form of steatosis in the 
pathogenesis of NASH. 
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Non-alcoholic fatty liver disease (NAFLD) is associated 
with visceral obesity, dyslipidemia and insulin resistance and 
has become a global threat with an estimated prevalence of 
15% to 30% of the general population [1, 2]. NAFLD covers a 
spectrum of liver disease ranging from lipid accumulation 
(simple steatosis) to non-alcoholic steatohepatitis (NASH). 
NASH is characterized by steatosis with lobular 
inflammation which can further progress to liver fibrosis and 
cirrhosis [3]. The pathophysiology that leads to NASH is not 
well understood, in particular the relationship between the 
development of steatosis and lobular inflammation is unclear.  
Morphologically, hepatic steatosis can manifest in two 
forms of lipid accumulation, i.e. macrovesicular or 
microvesicular steatosis. In macrovesicular steatosis, 
hepatocytes contain a large, single vacuole of fat which fills 
the cytoplasm and displaces the nucleus to the periphery (see 
[4] and references therein). By contrast, hepatocytes with 
microvesicular steatosis contain many small lipid droplets in 
the cytoplasm [4]. Emerging data indicate that excessive lipid 
accumulation in liver cells causes lipotoxic hepatocellular 
injury and inflammation [5]. Lobular inflammation in NASH 
is characterized by the presence of inflammatory aggregates, 
i.e. cell clusters containing different types of immune cells 
such as neutrophils, lymphocytes and macrophages [6, 7]. This 
inflammation is associated with activation of pro-fibrotic 
signaling cascades involving stellate cells and the production 
of collagen [6, 8]. To date, it is unclear whether the 
development of inflammation is linked to a specific form of 
steatosis, i.e. macro- or microvesicular steatosis. 
To identify a potential relationship between the two forms 
of steatosis and development of lobular inflammation (and 
the progression to fibrosis), we investigated in a longitudinal 
study the development of macro- and microvesicular 
steatosis and lobular inflammation up to the stage of early 
fibrosis. For this we used ApoE*3Leiden.CETP (E3L.CETP) 
transgenic mice which have a humanized lipoprotein 
metabolism and develop NASH in the context of obesity and 
dyslipidemia [7, 9]. These mice were treated with a 
NASH-inducing high-fat diet containing 24% lard fat and 1% 
cholesterol (HFC) for 12 weeks and compared to low-fat diet 
controls. Groups of mice were sacrificed in monthly intervals 
until NASH with early fibrosis had developed. NAFLD 
pathology was scored blindly using a recently established 
grading system for rodents which is based on the human 
NAS system [10]. Histological analyses and biochemical 
measurements in conjunction with transcriptome analysis 
revealed a positive association between macrovesicular 
steatosis and lobular inflammation as well as early fibrosis. 
These findings were confirmed in independent studies using 
diet-inducible models of NASH (i.e. C57BL/6J and 
LDLr-/-.Leiden mice) and the results showed that 
macrovesicular steatosis has a critical role in the 
pathogenesis of NASH.    
Materials and Methods 
Animal time-course experiment  
Experiments were approved by an independent Animal 
Care and Use Committee and were in compliance with 
European Community specifications regarding the use of 
laboratory animals. APOE*3Leiden (E3L) mice were 
cross-bred with transgenic mice that express human- 
cholesteryl ester transfer protein (CETP) to obtain 
heterozygous E3L.CETP mice [9]. Male E3L.CETP mice 
(n=70, 16-19 weeks of age) were used in the present study. 
All animals were housed in a temperature-controlled room 
with 12-hour light-dark cycling and had ad libitum access to 
food and water. Mice received a low fat diet (LFD; 10 kcal% 
lard, Research Diets, New Brunswick, NJ, USA) during a 
4-week run-in period. Mice were matched for body weight, 
plasma cholesterol and triglycerides and one group (n=10) 
was sacrificed to define the condition at the start of the 
experiment (t=0). Remaining mice were matched into 6 
groups. Three groups (n=10/group) were treated with a 
NASH-inducing high-fat diet (HFD; D12451; 45 kcal% lard, 
Research Diets, New Brunswick NJ, USA) supplemented 
with 1% (w/w) cholesterol (HFC) [7].  As reference for 
transcriptome analysis, three groups (n=10/group) received a 
HFD control diet. At 4-week intervals, food intake and body 
weight were determined and EDTA plasma was collected 
from the tail vein after 5h of fasting. Mice were sacrificed 
after 4, 8 or 12 weeks of diet feeding by CO2 asphyxiation. 
The medial liver lobe was fixed in formalin and embedded in 
paraffin for histological analysis of NAFLD and the left 
lateral liver lobe (lobus sinister hepatis) was snap frozen in 
liquid nitrogen and stored at -80°C for liver lipids, 
biochemical and gene expression analyses. White adipose 
tissue was collected, weighed and stored at -80°C.  
Histological evaluation of NAFLD  
NASH development was assessed histologically in 
hematoxylin and eosin (HE)-stained liver sections (3 μM) 
using an adapted scoring method for human NASH [10]. 
Briefly, steatosis was determined at a 40-100x magnification 
and quantified as macrovesicular and microvesicular 
steatosis, expressed as the percentage of the total surface area. 
Hepatic inflammation was analyzed by counting the number 
of inflammatory aggregates in five fields per specimen at a 
100x magnification (view size 3.1 mm2). Inflammatory cell 
aggregate counts were expressed as the average number of 
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aggregates per field. Early liver fibrosis was evaluated by 
collagen staining using Picro-Sirius Red (Chroma, 
WALDECK-Gmbh, Münster, Germany). The level of 
collagen deposition in the perisinusoidal area was determined 
relative to the total perisinusoidal area and expressed as a 
percentage. Correlation between the two forms of steatosis 
and lobular inflammation were made and validated in 
independent NASH studies with C57BL/6J mice and 
LDLr-/-.Leiden mice. More specifically, male C57BL/6J 
mice (n=12, 12 weeks of age) were treated with the above 
specified HFD (D12451) for 24 weeks to induce NASH. 
NAFLD was histologically scored to investigate the potential 
relationship between micro-/macrovesicular steatosis and 
lobular inflammation. Male LDLr-/-.Leiden mice (n=12, 
12-16 weeks of age) were treated with HFD for 34 weeks to 
induce a NASH phenotype with liver fibrosis to investigate 
the association between steatosis and fibrosis. These models 
can develop NASH after long-term HFD feeding (>20 weeks) 
with marked lobular inflammation [10, 11]. 
Liver lipid analysis 
The intrahepatic concentration of free cholesterol 
triglycerides, and cholesteryl esters was analyzed as 
described [7]. Briefly, lipids were extracted from liver 
homogenates using the Bligh and Dyer method and separated 
by high performance thin layer chromatography (HPTLC) on 
silica gel plates. Lipid spots were stained with color reagent 
(5g of MnCl24H2O, 32 ml of 95-97% H2SO4 added to 960 ml 
of CH3OH:H2O 1:1 v/v) and triglycerides, cholesteryl esters 
and free cholesterol were quantified using TINA version 2.09 
software (Raytest, Straubenhardt, Germany).  
Biochemical analysis of metabolic parameters  
Plasma levels of total cholesterol and triglycerides were 
measured with commercially available kits (Roche 
Diagnostics, Almere, The Netherlands). Plasma glucose was 
determined using the “Freestyle glucose measurement system” 
(Abbott, Heerlen, The Netherlands). Plasma insulin was 
quantified by ELISA (Mercodia, Uppsala, Sweden). Serum 
alanine transaminase (ALT) (GPT, cat. no. 10745138) and 
aspartate aminotransferase (AST) (GOT, cat. no. 10745120) 
activities were measured using Reflotron® kits (Roche 
Diagnostics). 
RNA isolation and gene expression analysis  
Transcriptome analysis was performed essentially as 
reported in [12] and references therein. Briefly, total RNA was 
extracted from individual livers using glass beads and 
RNAzol (Campro Scientific, Veenendaal, The Netherlands). 
After quality control of RNA integrity using RNA 6000 
Nano Lab-on-a-Chip kit and a bioanalyzer 2100 (Agilent 
Technologies), biotinylated cRNA was prepared with an 
Illumina® TotalPrep™ RNA Amplification Kit (Ambion, 
art.No.AM-IL1791. Biotinylated cRNA was hybridized onto 
the MouseRef-8 Expression BeadChip (Illumina) by a 
service provider (Service XS, Leiden, the Netherlands). 
Genomestudio v1.1.1 software (Illumina) was used for 
subsequent gene expression analysis. Differentially 
expressed probes were identified using the limma package of 
R/Bioconductor. Differentially expressed probes were 
selected based on the cut-off value False discovery rate (FDR) 
<0.05. Selected differentially expressed probes were used as 
an input for pathway analysis using Ingenuity Pathway 
Analysis suite (http://www.ingenuity.com).  
Statistical Analysis  
Data are presented as mean ± SEM. Significant 
differences between more than two groups were estimated by 
one-way ANOVA and Tukey post-hoc analysis (parametric 
samples) or Kruskal-Wallis followed by Mann-Whitney U 
tests (non-parametric samples). Significant differences 
between two groups were determined by two-sided Student’s 
t-test. Correlations between two variables were calculated by 
Spearman’s rank (non-normally distributed variables) or 
Pearson’s rank (normally distributed variables) correlation 
coefficient. A p-value<0.05 was considered statistically 
significant. GraphPad Prism software 6.0 was used for 
calculations (GraphPad Software, La Jolla, CA).  
Figure 1. Histological presentation of NASH in E3L.CETP mice. 
Representative photomicrographs of HE-stained liver cross-sections 
of E3L.CETP mice fed a high-fat diet supplemented with 1% 
cholesterol (HFC) for 0, 4, 8 and 12 weeks showing development 
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Table 1. Effect of HFC feeding on metabolic parameters over time. 
Parameter t=0 t=4 w t=8 w t=12 w 
Body weight (g) 29.4±0.6a 36.0±1.0b 42.2±1.6c 47.6±2.0d 
Epididymal fat (g) 0.4±0.1a 1.8±0.3b 2.3±0.2bc 2.5±0.2c 
Mesenteric fat (g) 0.3±0.0a 0.5±0.1a 0.8±0.1b 0.8±0.1b 
Liver (g) 1.8±0.1a 1.8±0.1a 2.4±0.2b 3.1±0.2c 
Hepatic lipids (µg/mg protein):     
Triglycerides 83.5±11.9a 171.9±86.6b 321.5±41.8c 304.6±35.8c 
Cholesteryl esters 17.9±2.7a 51.3±4.8b 65.8±5.0bc 82.8±6.7c 
Free cholesterol 16.9±1.3a 19.2±1.5a 27.6±1.6b 30.5±2.3c 
Serum levels, fasting:     
ALT (U/L) 121.7±10.0a 151.2±39.7a 100.8±21.7a 304.8±53.6b 
AST (U/L) 270.0±21.3a 341.2±111.6ab 171.9±20.9b 519.6±80.8c 
Plasma levels, fasting:     
Glucose (mM) 9.5±0.8a 12.3±0.9b 15.7±0.7c 16.0±0.7c 
Insulin (ng/mL) 0.4±0.1a 2.4±0.6b 2.2±0.4b 4.4±0.8c 
Cholesterol (mM) 6.7±0.7a 13.3±1.1b 13.7±2.7b 25.9±2.0c 
Triglycerides (mM) 3.3±0.5a 2.9±0.3a 2.2±0.6a 6.7±1.1b 
Mice were fed a high-fat diet supplemented with 1% (w/w) cholesterol (HFC) diet and groups (n=10) were 
sacrificed at regular intervals (t=0, t=4, t=8 or t=12 weeks). Values are mean±SEM. a,b,c,d Mean values within a 
row with unlike superscript letters are significantly different (p<0.05). 
Results 
HFC feeding leads to liver steatosis and lobular 
inflammation in context of obesity, dyslipidemia and 
insulin resistance   
E3L.CETP mice were treated with HFC up to 12 weeks. 
Histological analysis of livers showed that HFC-treated mice 
developed moderate pericentral steatosis after 4 weeks 
(Figure 1). This early steatosis consisted mainly of 
microvesicular steatosis. Steatosis intensified until the end of 
the study (at 12 weeks) and macrovesicular steatosis became 
more abundant. The development of steatosis can be 
attributed to a significant increase in liver lipids such as 
triglycerides (Table 1). With regards to lobular inflammation, 
first inflammatory cell aggregates were observed after 4 
weeks of HFC feeding and more inflammatory aggregates 
were present at the end of the study (Figure 1). During the 
experiment, mice developed an obese phenotype with a 
significant increase in body weight and visceral (epididymal 
and mesenteric) white adipose tissue (Table 1). Furthermore, 
HFC treatment induced dyslipidemia as demonstrated by 
significant elevations in plasma cholesterol and triglycerides. 
Mice developed insulin resistance as reflected by increased 
fasting insulin and glucose concentrations in plasma. Liver 
enzymes AST and ALT were significantly elevated at the end 
of the study demonstrating that HFC feeding resulted in 
hepatocellular damage. In all, HFC feeding resulted in 
development of NASH in context of diet-induced obesity, 
dyslipidemia and insulin resistance.    
Macrovesicular steatosis is positively associated with 
development of lobular inflammation 
In a more refined histopathological analysis, we quantified 
the two forms of steatosis as well as the number 
inflammatory aggregates during HFC feeding. At already 4 
weeks of HFC treatment, a pronounced and significant 
increase in microvesicular steatosis was observed (38%, 
p<0.05; Figure 2A). After this rapid induction, 
microvesicular steatosis remained at a constant elevated level 
until the end of the study. By contrast, macrovesicular 
steatosis showed a gradual and continuous development over 
time (24% at week 12, p<0.05; Figure 2B). The number of 
inflammatory cell aggregates increased significantly after 4 
weeks and showed a further increase at 12 weeks of HFC 
treatment (Figure 2C). Next, we examined whether a 
potential relationship exists between micro-/macrovesicular 
steatosis and lobular inflammation. Correlation analysis 
revealed a positive association between macrovesicular 
steatosis and inflammatory cell aggregates (r=0.45; p=0.01; 
Figure 2D). By contrast, microvesicular steatosis and total 
hepatic triglyceride content were not correlated with 
inflammatory cell aggregates (r=0.05; p=0.8 and r=-0.05; 
p=0.8, respectively). Together, these results indicate that a 
specific type of steatosis, macrovesicular steatosis, is critical 
for the development of lobular inflammation in NASH.  
Macrovesicular steatosis and inflammatory cell aggregates 
are associated independent of the disease model 
The positive association between macrovesicular steatosis 
and lobular inflammation observed in E3L.CETP mice was 
examined in other models of obesity-induced NASH.  More 
specifically, we examined livers of a mild experimental 
model (HFD-treated C57BL/6J mice) and a more severe 
model (HFD-treated LDLr-/-.Leiden mice). C57BL/6J mice 
developed steatosis (macrovesicular: 23.3±2.2%; 
microvesicular: 59.5±2.0% of total surface area) with modest 
inflammation (inflammatory aggregates: 2.0±0.5 per 
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microscopic field) (Figure 3A). LDLr-/-.Leiden mice also 
developed steatosis (macrovesicular: 26.5±2.3%; and 
microvesicular: 30.5±2.5% of total surface area), but more 
inflammatory aggregates (45.9±12.6 per microscopic field) 
and marked fibrosis (23.4±5.1%) (Figure 3A). To examine 
the relationship between macrovesicular steatosis and 
inflammation, we compared mice with a high and low level 
of macrovesicular steatosis, and comparable microvesicular 
steatosis. In both NASH models, macrovesicular steatosis 
above 20% was associated with significant increases in 
inflammatory aggregates (Figure 3B-C). Again, 
macrovesicular steatosis was positively correlated with 
inflammatory aggregates (C57BL/6J: r=0.66, and 
LDLr-/-.Leiden: r=0.77; both p<0.05), while no correlation 
was observed for microvesicular steatosis (not shown). 
Macrovesicular steatosis is associated with the development 
of fibrosis  
Next, we investigated whether there is a link between the 
development of macrovesicular steatosis and liver fibrosis. 
Sirius red staining of livers from the time course experiment 
in E3L.CETP mice showed mild perihepatocellular fibrosis 
at end point (12 weeks of HFC treatment) (Figure 4A). 
Specifically for the 12-week time point, we observed a 
significant upregulation of genes involved in pro-fibrotic 
pathways including TGF, TIMP-1, Col1α1, Col1α2 and 
MMP13 (Figure 4B) as demonstrated by microarray pathway 
analysis. Of note, this onset of fibrosis was observed when 
macrovesicular steatosis reached levels above 20%. The 
relationship between macrovesicular steatosis and liver 
fibrosis was further examined in a NASH model with 
pronounced fibrosis, namely LDLr-/-.Leiden mice (Figure 
4C). LDLr-/-.Leiden mice with a high percentage of 
macrovesicular steatosis (>20%) exhibited more fibrosis than 
mice with a low level of macrovesicular steatosis (≤20%) 
(Figure 4D). Furthermore, the level of macrovesicular 
Figure 2. Quantitative histological analysis of the development of liver steatosis and inflammation in 
E3L.CETP mice. Quantification of the two steatosis forms (A) microvesicular steatosis and (B) macrovesicular 
steatosis expressed as percentage (%) of the total surface area. Microvesicular steatosis developed rapidly after 4 
weeks of HFC and levels remained constant over time, whereas macrovesicular steatosis developed continuously. 
(C) Lobular inflammation (expressed as the number of inflammatory cell aggregates per field) was induced already 
after 4 weeks of HFC, but increased strongly after 12 weeks of HFC feeding. (D) Macrovesicular steatosis is 
positively correlated with inflammatory cell aggregates as determined by Spearman’s rank correlation analysis. a,b,c,d 
Mean values with unlike letters differ significantly from each other (p≤0.05). 
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steatosis correlated positively with the amount of liver 
fibrosis (r=0.67, p<0.05, Figure 4E) while there was no 
correlation between microvesicular steatosis and fibrosis. Of 
note, the number of inflammatory cell aggregates is strongly 
correlated with fibrosis (r=0.93, p<0.001). Thus, the 
association between macrovesicular steatosis and fibrosis is 
likely to be a consequence of the development of 
macrovesicular steatosis-associated lobular inflammation. 
Altogether, these results support the importance of 
macrovesicular steatosis in the etiology of liver inflammation 
and, as a consequence thereof, liver fibrosis.  
Discussion 
This study analyzed the progression of steatosis and 
inflammation during the pathogenesis of NASH in obesity. 
Specifically, we examined the relationship between the 
development of specific forms of steatosis and inflammatory 
cell aggregates in different diet-induced NASH models. In 
E3L.CETP mice treated with a high-fat diet containing 1% 
w/w cholesterol (HFC), a rapid induction of microvesicular 
steatosis was observed (at week 4). This form of steatosis 
remained at an elevated level and did not further progress. By 
contrast, macrovesicular steatosis showed a progressive 
development until the end of the study (week 12). 
Development of macrovesicular steatosis correlated 
positively with the number of inflammatory cell aggregates, 
whereas microvesicular steatosis did not correlate with 
inflammation. Further support for a positive association 
between macrovesicular steatosis and lobular inflammation 
was obtained from independent NASH studies in 
HFD-treated C57BL/6J and LDLr-/-.Leiden. Furthermore, 
macrovesicular steatosis was positively associated with 
perihepatocellular fibrosis in LDLr-/-.Leiden mice, a mouse 
model that develops pronounced liver fibrosis on a HFD. 
Collectively, these results highlight the importance of  
Figure 3. Histological representation and the role of macrovesicular steatosis in other 
diet-induced NASH mouse models. Representative photographs of HE-stained liver 
cross-sections from (A) male C57BL/6J mice fed a high-fat diet (HFD) for 24 weeks and male 
LDLr-/-.Leiden mice treated with HFD for 34 weeks. Photomicrographs on the left show C57BL/6J 
and on the right LDLr-/-.Leiden mice (Magnification: 200x). (B) C57BL/6J mice with high levels of 
macrovesicular steatosis (>20%) showed more inflammatory cell aggregates then mice with low 
levels of macrovesicular steatosis (≤ 20%), while microvesicular steatosis was comparable (high vs. 
low macrovesicular steatosis: ±53% vs. ±60%, respectively). (C) LDLr-/-.Leiden mice with high levels 
of macrovesicular (>20%) have increased lobular inflammation compared to mice with low 
macrovesicular steatosis (≤20%), while microvesicular steatosis was comparable between the 
groups (both, ±30%). 
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Figure 4. Onset of liver fibrosis is induced after 12 weeks of HFC feeding in E3L.CETP mice. (A) Representative photomicrograph of 
pico-sirius red-stained livers showing mild fibrosis (Magnification 100x). Arrows show perihepatocellular fibrosis. (B) Transcriptome 
analysis confirmed the onset of liver fibrosis as demonstrated by upregulation of pro-fibrotic signaling pathways in hepatic stellate cells and 
showed increased expression of pro-fibrotic genes including Col-1α, Timp1, Smad3. Nodes that are colored red (upregulated) or green 
(downregulated) indicate significant differences in fold-change in HFC-fed mice compared to HFD-fed control mice. (C) Representative 
photomicrograph of pico-sirius red-stained liver section showing pronounced fibrosis in LDLr-/-.Leiden mice treated with HFD feeding for 
34 weeks  (Magnification 100x). (D) LDLr-/-.Leiden mice with high levels of macrovesicular (>20%) have more fibrosis compared to mice 
with low macrovesicular steatosis (≤20%). (E) Macrovesicular steatosis is positively correlated with fibrosis in HFD-fed LDLr-/-.Leiden 
mice.  
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macrovesicular steatosis in the pathogenesis of NASH.  
In the present study, the diet-induced NASH models 
showed pronounced development of microvesicular and 
macrovesicular steatosis. Our time course analysis in 
E3L.CETP mice revealed that the development of 
microvesicular steatosis is rapid process and plateau levels 
were reached after 4 weeks of HFC feeding. By contrast, 
macrovesicular steatosis developed continuously and 
progressively over time. The development of these two forms 
of steatosis is only poorly understood. It is not clear whether 
the small lipid vacuoles (microvesicular steatosis) fuse to 
form one large vacuole (macrovesicular steatosis), or 
whether macrovesicular and microvesicular steatosis develop 
independently from each other ([13] and references therein). 
The most widely accepted theory of lipid droplet biogenesis 
implies that neutral glycerol and esters accumulate within the 
phospholipid bilayer of the endoplasmatic reticulum (ER) 
and the bilayer gradually separates from the ER to form 
nascent phospholipid-coated lipid droplets which bud off into 
the cytosol [13-15]. The most common form of further growth 
of these droplets is expansion by diffusion of lipids (from the 
ER or cytosol), i.e. triglycerides are added to the cores and 
phospholipids as surfactants to the surfaces of a growing 
lipid droplet. Notably, the fusion of small lipid vacuoles to a 
large vacuole is considered to be a relatively rare event [13,14]. 
Thus, it is possible that the observed gradual development of 
macrovesicular steatosis may be determined by the amount 
of phospholipids that are available in a hepatocyte to enlarge 
the microvesicular structures.  
The large lipid droplets that are characteristic for 
macrovesicular steatosis can cause cellular stress and 
architectural changes to hepatocytes [13]. The injured liver 
cells then release immune reactive substances and 
hepatocellular damage will ultimately lead to ballooning, 
apoptosis and infiltration of immune cells [16]. Consistent 
with these processes, we observed a significant correlation 
between macrovesicular steatosis and immune cell 
aggregates in all models. Absence of a correlation between 
inflammatory cell aggregates and microvesicular steatosis 
suggests that the microvesicular lipid droplets are less 
harmful. The importance of macrovesicular steatosis as 
inducer of liver injury and subsequent liver fibrosis is 
supported by a recent study in rats [17]. A comparison of 
different rat strains with either 1) solely microvesicular 
steatosis (Lewis rats), 2) pure macrovesicular steatosis 
(Sprague Dawley), and 3) mixed-type steatosis (Wistar) 
showed that Sprague Dawley rats with macrovesicular 
steatosis had the highest degree of lobular inflammation and 
fibrosis [17]. In line with this, we observed that the marked 
increase in macrovesicular steatosis between 8 and 12 weeks 
of HFC feeding in E3L.CETP mice is accompanied by 
increased number of inflammatory cell aggregates, and onset 
of pathways leading to liver fibrosis. Furthermore, 
macrovesicular steatosis and inflammatory cell aggregates 
correlated significantly with the level of hepatocellular 
fibrosis in the LDLr-/-.Leiden mice.  
This study used different mouse strains and diets to 
investigate the development of NASH in the context of 
visceral obesity, insulin resistance and dyslipidemia, all of 
which constitute important risk factors of NAFLD in humans 
[1-3]. These risk factors are not or only inadequately mimicked 
in methionine choline deficient (MCD) diet-induced NAFLD 
or CCl4-induced liver fibrosis [18, 19]. It is generally assumed 
that diets low in methionine and choline are required to 
induce liver fibrosis [18]. However, the present study shows 
that liver fibrosis can also be induced with high-fat diets 
(HFD) containing 45 energy percent from fat, which is 
translational to human diets [20]. We have previously reported 
that LDLr-/-.Leiden mice develop a NASH phenotype on 
HFD which reflects human steatohepatitis [10]. We herein 
show that these animals develop pronounced liver fibrosis 
(>20% perihepatocellular fibrosis) when the HFD treatment 
is prolonged (34 weeks). Consistent with this observation, 
others reported that mice on a LDLr-/- background constitute 
a physiological model particularly vulnerable to study the 
inflammation in NAFLD [21].  
High-fat diets are often supplemented with cholesterol to 
induce chronic liver inflammation. In LDLr-/- mice, Bieghs 
and coworkers demonstrated that cholesterol feeding can 
cause lysosomal cholesterol accumulation in Kupffer cells 
which correlates with hepatic inflammation and cholesterol 
crystallization [22]. Similarly, E3L mice treated with a 
Western-type diet containing 1% (w/w) cholesterol for 20 
weeks show formation of cholesterol crystals and collagen 
deposition in liver [23] as they have been described in humans 
with NASH [24]. Consistent with this pro-fibrotic effect of 
dietary cholesterol, HFC-fed E3L.CETP mice developed 
early fibrosis after already 12 weeks, and transcriptome 
analysis substantiated the activation of pro-fibrotic signaling 
pathways in liver controlled by TNFα, PDGF and TGF. The 
same pathways were activated in mouse liver with high (1% 
w/w), but not low (0.25% w/w) dietary cholesterol [25]. This 
effect was attributable to dietary cholesterol itself and not to 
the fat content of the diet. Therefore, it is likely that 
NASH-inducing diets containing high concentrations of 
cholesterol accentuate the above mentioned inflammatory 
pathways, and that other inflammatory pathways which also 
may contribute to NASH development (e.g. IL-6 and leptin 
signaling) have a relative lower contribution.  
In all, our data highlight the importance of macrovesicular 
steatosis in the pathogenesis of experimental diet-induced 
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NASH, because this form steatosis is tightly associated with 
cellular lobular inflammation and perihepatocellular fibrosis. 
Our study advocates a more refined morphological analysis 
of steatosis subtypes in addition to biochemical liver lipid 
analysis. Such an analysis may be of particular relevance for 
efficacy studies that test nutritional or pharmaceutical 
interventions.   
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